GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL
Dose-escalation Sequention Cohort Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GNR-084 in Patients With Refractory or Relapse Acute Lymphoblastic B-cell Precursor Leukemia.
Sponsor: AO GENERIUM
A PHASE1/PHASE2 clinical study on ALL and B-precursor Acute Lymphoblastic Leukemia, this trial is actively recruiting participants. The trial is conducted by AO GENERIUM and has accumulated 9 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Recruiting PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Apr 2024 — Jul 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Mar 2023 — Apr 2024 [monthly]
Recruiting PHASE1_PHASE2
▶ Show 4 earlier versions
-
Nov 2021 — Mar 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2021 — Nov 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Oct 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AO GENERIUM
For direct contact, visit the study record on ClinicalTrials.gov .